| Drug ID: | Drug13 |
|---|---|
| Drug Name: | Celecoxib |
| CID: | 2662 |
| DrugBank ID: | DB00482 |
| Modality: | Small Molecule |
| Groups: | approved|investigational |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00640809, , NCT05960864 |
| Molecular Formula: | C17H14F3N3O2S |
| Molecular Weight: | 381.4 g/mol |
| Isomeric SMILES: | CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F |
| Synonyms: | celecoxib; 169590-42-5; Celebra; Onsenal; Celecox; 184007-95-2; Xilebao; YM177; YM 177; HSDB 7038 |
| Phase 0: | 13 |
| Phase 1: | 112 |
| Phase 2: | 227 |
| Phase 3: | 121 |
| Phase 4: | 111 |
| Description: | Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt110 | 2662 | Celecoxib | 1576 | CYP3A4 | Homo sapiens (human) | None | |
| dt111 | 2662 | Celecoxib | 4513 | COX2 | Homo sapiens (human) | None | |
| dt112 | 2662 | Celecoxib | 5743 | PTGS2 | Homo sapiens (human) | Cyclooxygenase-2 inhibitor | |
| dt113 | 2662 | Celecoxib | 5742 | PTGS1 | Homo sapiens (human) | None | |
| dt114 | 2662 | Celecoxib | 5743 | PTGS2 | Homo sapiens (human) | None | |
| dt115 | 2662 | Celecoxib | 1376 | CPT2 | Homo sapiens (human) | Inhibitor | |
| dt116 | 2662 | Celecoxib | 774 | CACNA1B | Homo sapiens (human) | None | |
| dt117 | 2662 | Celecoxib | 7422 | VEGFA | Homo sapiens (human) | None | |
| dt118 | 2662 | Celecoxib | 55799 | CACNA2D3 | Homo sapiens (human) | None | |
| dt119 | 2662 | Celecoxib | 489 | ATP2A3 | Homo sapiens (human) | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT05960864 | Chinese Spondyloarthritis Inception Cohort (CESPIC) | None | NOT_YET_RECRUITING | Southwest Hospital, China | Ankylosing Spondylitis (AS) / Radiographic Axial … | DRUG: Celecoxib | Details |
| NCT00640809 | Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole | PHASE4 | COMPLETED | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Bowel Diseases, Inflammatory | DRUG: Celecoxib; OTHER: Placebo; DRUG: Ibuprofen … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Camptothecin-loaded chondroitin sulfate-celecoxib reduction-sensitive micelles …
PMID: 40409631
Year: 2025
Relationship Type:
Treatment
Score: 9.5
Studies have shown that inflammation is closely linked to the cancer development, and the patients with inflammatory bowel disease (IBD) have a highe…
Optimization of alginate/carboxymethyl chitosan microbeads for the sustained re…
PMID: 39476907
Year: 2024
Relationship Type:
Treatment
Score: 9.5
Multiple anti-inflammatory medications have helped treat inflammatory bowel disease (IBD). However, oral administration has minimal absorption and sy…
Amphiphilic Celecoxib-Polysaccharide Delivery System for Enhanced Colon-Targete…
PMID: 40284506
Year: 2025
Relationship Type:
Treatment
Score: 9.5
Background: Ulcerative colitis (UC), a subtype of chronic inflammatory bowel disease (IBD), is primarily treated with oral medications to reduce infl…
Fabrication and Evaluation of Celecoxib Oral Oleogel to Reduce the Inflammation…
PMID: 34129135
Year: 2021
Relationship Type:
Association
Score: 9.5
Oleogel consists of hydrophobic solvent and an oleogelator. In this study, attempts were made to study the influence of Celecoxib solubility, concent…
Lipid-based nanocarrier-mediated targeted delivery of celecoxib attenuate sever…
PMID: 32806257
Year: 2020
Relationship Type:
Treatment
Score: 9.5
Ulcerative colitis is a chronic mucosal inflammatory condition that adversely affects colon and rectum. Celecoxib is a selective inhibitor of inducib…
pH-sensitive nanoparticles of curcumin-celecoxib combination: evaluating drug s…
PMID: 24375287
Year: 2014
Relationship Type:
Treatment
Score: 9.3
Inflammatory bowel diseases, which largely comprise ulcerative colitis (UC) and Crohn's disease, are increasingly posing as a global threat because o…
Cholestatic hepatitis with small duct injury associated with celecoxib
PMID: 23861685
Year: 2013
Relationship Type:
Adverse Effect
Score: 9.1
Drug-induced liver injury (DILI) is a common clinical entity but is underreported due to various reasons. Cyclooxygenase-2 inhibitors like Celecoxib …
Celecoxib alleviates the DSS-induced ulcerative colitis in mice by enhancing in…
PMID: 38156770
Year: 2024
Relationship Type:
Association
Score: 6.5
Safety evaluation of celecoxib in patients with ulcerative colitis in remission…
PMID: 34856782
Year: 2023
Relationship Type:
Association
Score: 6.5
Colon targeting of celecoxib nanomixed micelles using pulsatile drug delivery s…
PMID: 31870958
Year: 2020
Relationship Type:
Association
Score: 6.5
In Ethiopia, poultry production is an important source of domestic food and nutrition security while providing income for nearly 80% of Ethiopians. …
Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential phar…
PMID: 24462351
Year: 2014
Relationship Type:
Treatment
Score: 6.3
BACKGROUND: Autism spectrum disorders (ASDs) comprise a range of neurodevelopmental conditions of varying severity, characterized by marked qualita…